Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways
The multifunctional anti-apoptotic Bag-1 protein has important roles in apoptosis, proteasome-mediated degradation, transcriptional regulation, and intracellular signaling. Bag-1 promotes cell survival and proliferation, and is overexpressed in breast cancer. Therefore, Bag-1-targeted therapy might be a promising strategy to treat breast cancer. However, the effects of Bag-1 silencing in combination with conventional chemotherapeutic drugs on cell viability and major signaling pathways have not yet been fully investigated in breast cancer cells. In this study, we investigated the cytotoxic effects of Bag-1 silencing, alone and in combination with cisplatin or paclitaxel treatment, in MCF-7 breast cancer cells. Bag-1 knockdown by shRNA or siRNA transfection sensitized MCF-7 cells to apoptosis induced by cisplatin or paclitaxel. Combination of Bag-1 silencing and drug treatment more potently downregulated the pro-survival PI3K/Akt/mTOR and p44/42 mitogen activated protein kinase (MAPK) pathways, and more potently upregulated the stress-activated p38 and SAPK/JNK MAPK pathways. Bag-1-silenced drug-treated cells had also highly reduced proliferative capacity, downregulated cyclin–cyclin dependent kinase complexes and upregulated tumor suppressors p21 and Rb. These results overall indicated that Bag-1 silencing enhanced cisplatin- or paclitaxel-induced cytotoxicity through multiple pathways. In conclusion, Bag-1 targeted therapy might enhance the therapeutic potential of conventional anti-cancer drugs in the treatment of breast cancer.
KeywordsBag-1 siRNA/shRNA Chemotherapeutic agents Apoptosis Breast cancer MAPK PI3K/Akt/mTOR pathway
This work was supported by internal funds of Istanbul Technical University and Istanbul Kultur University Scientific Project Support Centers.
Compliance with ethical standards
Conflict of interest
Authors declare that there is no conflict of interest.
Research involving human participants and/or animals
There are no human participants and/or animals used in this study.
- 14.Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M et al (2014) Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res 26(5):564–572. https://doi.org/10.3978/j.issn.1000-9604.2014.08.20 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA et al (2014) Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther 22(7):1310–1319. https://doi.org/10.1038/mt.2014.27 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P et al (1994) Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem 269(9):7030–7035PubMedGoogle Scholar
- 33.Ozfiliz P, Kizilboga T, Demir S, Alkurt G, Palavan-Unsal N, Arisan ED et al (2015) Bag-1 promotes cell survival through c-Myc-mediated ODC upregulation that is not preferred under apoptotic stimuli in MCF-7 cells. Cell Biochem Funct 33(5):293–307. https://doi.org/10.1002/cbf.3114 CrossRefPubMedGoogle Scholar
- 35.Leggett S, Koczwara B, Miller M (2015) The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutr Cancer 67(3):373–391. https://doi.org/10.1080/01635581.2015.1004731 CrossRefPubMedGoogle Scholar